These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 25372546

  • 1. Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
    Grannis CH, Dewan VN, Wang RC.
    Retin Cases Brief Rep; 2014; 8(4):348-51. PubMed ID: 25372546
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Serous macular detachment in Waldenström macroglobulinemia: a report of four cases.
    Baker PS, Garg SJ, Fineman MS, Chiang A, Alshareef RA, Belmont J, Brown GC.
    Am J Ophthalmol; 2013 Mar; 155(3):448-55. PubMed ID: 23218691
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunogammopathies and acquired vitelliform detachments: a report of four cases.
    Rusu IM, Mrejen S, Engelbert M, Gallego-Pinazo R, Ober MD, Johnson MW, Leys A, Yannuzzi LA.
    Am J Ophthalmol; 2014 Mar; 157(3):648-57.e1. PubMed ID: 24321469
    [Abstract] [Full Text] [Related]

  • 9. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
    Waterman GN, Yellin O, Swift RA, Mapes R, Eades B, Ackerman E, Berenson JR.
    Ann Hematol; 2011 Feb; 90(2):193-200. PubMed ID: 20809423
    [Abstract] [Full Text] [Related]

  • 10. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E.
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [Abstract] [Full Text] [Related]

  • 11. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [Abstract] [Full Text] [Related]

  • 12. Cystoid macular edema associated with preservative-free latanoprost after uncomplicated cataract surgery: case report and review of the literature.
    Makri OE, Tsapardoni FN, Plotas P, Ifantis N, Xanthopoulou PT, Georgakopoulos CD.
    BMC Res Notes; 2017 Mar 20; 10(1):127. PubMed ID: 28320481
    [Abstract] [Full Text] [Related]

  • 13. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
    Al Faran A, Mousa A, Al Shamsi H, Al Gaeed A, Ghazi NG.
    Retina; 2014 Jun 20; 34(6):1208-15. PubMed ID: 24368308
    [Abstract] [Full Text] [Related]

  • 14. Phakic cystoid macular edema secondary to idiopathic macular telangiectasia type 1 responsive to topical anti-inflammatory agents.
    Dunn EN, Gregori NZ, Goldhardt R.
    Semin Ophthalmol; 2013 Mar 20; 28(2):84-7. PubMed ID: 23448562
    [Abstract] [Full Text] [Related]

  • 15. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.
    Cancer; 2006 Mar 15; 106(6):1316-9. PubMed ID: 16470606
    [Abstract] [Full Text] [Related]

  • 16. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H, Hayashi T, Nojima M, Yasui H, Ikeda Y, Ishida T, Adachi M, Imai K.
    Rinsho Ketsueki; 2005 Apr 15; 46(4):269-73. PubMed ID: 16444959
    [Abstract] [Full Text] [Related]

  • 17. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC, Farrell AT, Sridhara R, Pazdur R.
    Clin Cancer Res; 2006 May 15; 12(10):2955-60. PubMed ID: 16707588
    [Abstract] [Full Text] [Related]

  • 18. Visual acuity and microperimetric mapping of lesion area in eyes with inflammatory cystoid macular oedema.
    Munk MR, Kiss CG, Huf W, Montuoro A, Sulzbacher F, Kroh M, Larsen M, Schmidt-Erfurth U.
    Acta Ophthalmol; 2014 Jun 15; 92(4):332-8. PubMed ID: 23802743
    [Abstract] [Full Text] [Related]

  • 19. Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
    Malani AK, Gupta V, Rangineni R.
    Acta Haematol; 2006 Jun 15; 116(4):255-8. PubMed ID: 17119326
    [Abstract] [Full Text] [Related]

  • 20. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P, Gruppo Italiano Trapianti di Midollo.
    Haematologica; 2006 Jun 15; 91(6):837-9. PubMed ID: 16769588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.